Helixmith is a gene therapy company headquartered in Seoul, Korea, developing new and innovative biopharmaceuticals for previously untreated diseases, and is listed on KOSDAQ. The company has an extensive gene therapy pipeline, including a CAR-T program targeting several different types of solid tumors and an AAV vector program targeting neuromuscular diseases. Engensis (VM202), a more advanced pipeline candidate, is a plasmid DNA therapy being studied for DPN, diabetic foot ulcers, claudication, amyotrophic lateral sclerosis (Phase 2 beginning in late 2020), coronary artery disease and Charcot-Marie-Tooth disease. Helixmith clinical development activities are based in San Diego, California,
Company Details
- Employees
- 32
- Founded
- -
- Address
- Seoul National University, 1 Gwanak-Ro, Gwanak-Gu, 5th Fl. Bldg. 203,united States
- Phone
- 02-2102-7200
- Industry
- Biotechnology
- Website
- https://www.helixmith.com/
- HQ
- Seoul, Korea
Helixmith Questions
Helixmith's helpline number is 02-2102-7200
Helixmith's website is https://www.helixmith.com/
Helixmith's LinkedIn profile is https://www.linkedin.com/company/helixmith
Helixmith has
32 employees.
View email and phone details for 32
employees at Helixmith.
Helixmith's industry is
Biotechnology
Helixmith's categories are Biotechnology
Helixmith's founding year is 1996
